One in 26. That's how many people living in the United States, according to the Epilepsy Foundation and the CDC, will develop epilepsy at some point in their lifetime. There are over 150,000 new cases ...
Shares of Bright Minds Biosciences rose after the company released positive topline results from its phase two trial of a treatment for patients with drug-resistant Absence Seizures and Developmental ...
AIIMS Delhi has resumed free Therapeutic Drug Monitoring (TDM) tests for epilepsy patients. This initiative reduces financial ...
Bright Minds Biosciences has debuted glowing phase 2 results for its lead anti-seizure asset, giving the biotech’s stock a ...
Each year, about 20 % of the 70 million people who are evaluated in epilepsy clinics turn out to have seizures that cannot be identified by any physical cause in the brain. The trouble, which ...
The FDA has approved Ztalmy for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder, or CDD, in patients aged 2 years and older, according to a press release ...
CHICAGO -- Researchers say antiepilectic drug treatments administered when the brain is developing appear to trigger schizophrenia-like behavior in animal models. In humans, having a history of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback